Nova Eye (Australia) Today
| EYE Stock | 0.11 0.01 10.00% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Nova Eye is selling for under 0.11 as of the 20th of March 2025; that is 10.00 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.1. Nova Eye has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Moving together with Nova Stock
Moving against Nova Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nova Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Nova Eye's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nova Eye or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Founder Chairman | BEng BE |
| Thematic Idea | Drugs (View all Themes) |
| Business Concentration | Drugs, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) |
Nova Eye Medical (EYE) is traded on Australian Securities Exchange in Australia and employs 14 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nova Eye's market, we take the total number of its shares issued and multiply it by Nova Eye's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nova Eye Medical operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 263.24 M outstanding shares.
Nova Eye Medical has accumulated about 7.42 M in cash with (7.73 M) of positive cash flow from operations.
Check Nova Eye Probability Of Bankruptcy
Ownership AllocationNova Eye Medical maintains a total of 263.24 Million outstanding shares. Nova Eye Medical secures 16.17 % of its outstanding shares held by insiders and 16.31 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nova Ownership Details
Nova Eye Medical Risk Profiles
Although Nova Eye's alpha and beta are two of the key measurements used to evaluate Nova Eye's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.71 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.44 | |||
| Risk Adjusted Performance | (0.04) |
Nova Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Nova Eye without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Nova Eye Corporate Management
Elected by the shareholders, the Nova Eye's board of directors comprises two types of representatives: Nova Eye inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Eye's management team and ensure that shareholders' interests are well served. Nova Eye's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Eye's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc FAICD | Advisor Board | Profile | |
| Keith Byrne | Vice Operations | Profile | |
| BEc CA | Company Secretary | Profile | |
| Bill Swaim | Pres Ellex | Profile | |
| Mark Flynn | Investor Relations | Profile |
Additional Tools for Nova Stock Analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.